ArticleHeart (British Cardiac Society)2025
Surveillance of left ventricular function among cancer survivors.
Article in Heart (British Cardiac Society), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Tests for Stage B Heart Failure.Current cardiology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer survivors have an increased risk of heart failure, but this is balanced by the risk of death from other causes. The results of this balance impact on the optimal time for guideline-recommended surveillance for cardiac dysfunction. This study aimed to investigate the association between cancer history and cardiac function at various times during follow-up.
methodsThis cross-sectional study included participants with documented cancer history from cancer registries and matched with non-cancer controls using propensity scoring based on age, sex, diabetes and blood pressure. Cardiac function, primarily left ventricular ejection fraction (LVEF), was assessed using cardiac magnetic resonance (CMR). Multivariable binomial regression analyses were conducted to analyse the association between cancer and cardiac function.
resultsOf 23 854 cancer survivors (aged 61.0±6.8 years, 60.9% female) and an equal number of matched controls, 1051 survivors and 1538 controls underwent CMR. Survivors from breast or haematological malignancies demonstrated minor differences in LVEF (59.5±6.4 vs 60.1±6.4, p<0.001) and global circumferential strain (-22.4±3.5 vs -22.6±3.5, p<0.001) compared with controls. Analysis stratified by time since cancer diagnosis revealed that both LVEF (p=0.014) and global circumferential strain (p=0.045) were less likely to be impaired with increasing time from diagnosis. Cancer survivors (prevalence ratio (PR)=1.19 (95% CI 1.05 to 1.35), p=0.006), particularly breast cancer (PR=1.39 (95% CI 1.18 to 1.64), p<0.001), were associated with low LVEF (≤55%) after adjusting for age, sex, years since cancer diagnoses and blood pressure medication.
conclusionsCompared with people without cancer, cancer survivors have a higher risk of subclinical cardiac dysfunction. However, dysfunction is less common with increasing time since cancer diagnosis. These findings suggest prioritising cardiac monitoring early in survivorship, especially in breast cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.